[Comment] Bipolar androgen therapy: an intriguing paradox

In The Lancet Oncology, Benjamin A Teply and colleagues1 report a phase 2 trial in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor pathway inhibitor, enzalutamide, who were treated with bipolar androgen therapy (BAT). It is a novel and intriguing concept.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research